Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 2
1986 8
1987 5
1988 2
1989 8
1990 9
1991 9
1992 8
1993 11
1994 1
1995 8
1996 16
1997 19
1998 22
1999 22
2000 17
2001 23
2002 13
2003 35
2004 26
2005 23
2006 22
2007 31
2008 56
2009 47
2010 54
2011 50
2012 62
2013 49
2014 36
2015 61
2016 38
2017 24
2018 35
2019 32
2020 35
2021 27
2022 21
2023 25
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

929 results

Results by year

Filters applied: . Clear all
Page 1
Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France.
Seng R, Frange P, Faye A, Dollfus C, le Chenadec J, Boufassa F, Essat A, Goetghebuer T, Arezes E, Avettand-Fènoël V, Bigna JJ, Blanche S, Goujard C, Meyer L, Warszawski J, Viard JP; ANRS EPF; COVERTE; PRIMO; SEROPRI; COPANA study groups. Seng R, et al. Lancet Reg Health Eur. 2024 Apr 1;40:100885. doi: 10.1016/j.lanepe.2024.100885. eCollection 2024 May. Lancet Reg Health Eur. 2024. PMID: 38576825 Free PMC article.
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.
Palich R, Arias-Rodríguez A, Duracinsky M, Le Talec JY, Rousset Torrente O, Lascoux-Combe C, Lacombe K, Ghosn J, Viard JP, Pialoux G, Ohayon M, Duvivier C, Velter A, Ben Mechlia M, Beniguel L, Grabar S, Melchior M, Assoumou L, Supervie V; GANYMEDE study group; Collaborators. Palich R, et al. Euro Surveill. 2024 Mar;29(11):2300445. doi: 10.2807/1560-7917.ES.2024.29.11.2300445. Euro Surveill. 2024. PMID: 38487889 Free PMC article.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Johnson MG, Strizki JM, Jensen E, Cohen J, Katlama C, Fishchuk R, Ponce-de-León A, Fourie N, Cheng C-Y, McCoy D, Vesnesky M, Norice CT, Zhang Y, Williams-Diaz A, Brown ML, Carmelitano P, Grobler JA, Paschke A, De Anda C. Johnson MG, et al. Among authors: katlama c. Microbiol Spectr. 2024 Mar 5;12(3):e0356323. doi: 10.1128/spectrum.03563-23. Epub 2024 Feb 1. Microbiol Spectr. 2024. PMID: 38299867 Free PMC article. Clinical Trial.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Information and communication are key for hepatitis B elimination in Francophone Africa: Insights from a survey among healthcare providers.
Wandeler G, Ramirez Mena A, Kouanfack C, Fortes L, Ndione AG, Debzi N, Lacombe K, Katlama C, Ekouevi DK; for AFRAVIH. Wandeler G, et al. Among authors: katlama c. J Virus Erad. 2023 Sep 6;9(3):100346. doi: 10.1016/j.jve.2023.100346. eCollection 2023 Sep. J Virus Erad. 2023. PMID: 37954476 Free PMC article. No abstract available.
Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
Mazouz F, Bertine M, Coppée R, Storto A, Katlama C, Landman R, Cabié A, Peytavin G, Raffi F, Yazdanpanah Y, Descamps D, Joly V, Ghosn J, Charpentier C; LAMIDOL Study Group. Mazouz F, et al. Among authors: katlama c. J Antimicrob Chemother. 2023 Dec 1;78(12):2995-3002. doi: 10.1093/jac/dkad344. J Antimicrob Chemother. 2023. PMID: 37930812 Clinical Trial.
A truncated HIV Tat demonstrates potent and specific latency reversal activity.
Van Gulck E, Pardons M, Nijs E, Verheyen N, Dockx K, Van Den Eynde C, Battivelli E, Vega J, Florence E, Autran B, Archin NM, Margolis DM, Katlama C, Hamimi C, Van Den Wyngaert I, Eyassu F, Vandekerckhove L, Boden D. Van Gulck E, et al. Among authors: katlama c. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0041723. doi: 10.1128/aac.00417-23. Epub 2023 Oct 24. Antimicrob Agents Chemother. 2023. PMID: 37874295 Free PMC article.
CD8 + T-cell priming is quantitatively but not qualitatively impaired in people with HIV-1 on antiretroviral therapy.
Cabral-Piccin MP, Briceño O, Papagno L, Liouville B, White E, Perdomo-Celis F, Autaa G, Volant S, Llewellyn-Lacey S, Fromentin R, Chomont N, Price DA, Sáez-Cirión A, Lambotte O, Katlama C, Appay V. Cabral-Piccin MP, et al. Among authors: katlama c. AIDS. 2024 Feb 1;38(2):161-166. doi: 10.1097/QAD.0000000000003746. Epub 2023 Oct 5. AIDS. 2024. PMID: 37800637
929 results